Please assess the completion status of the following clinical trial:

Trial Title: Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be eligible for inclusion in the study, each patient must fulfill each of the criteria below.~* Have provided written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.~* Be female and 18 years of age or older.~* Have histologically confirmed invasive breast cancer.~* High risk of breast cancer recurrence (\> 25% within the first 5 years without adjuvant therapy, \> 35% within the first 10 years) with one of the following:~  * Regional node positive disease (pN+; tumor cells or tumor cell clusters \< 0.2 mm in diameter are not counted as metastases);~ * Pathological N0 and PgR- and tumor size \> 20 mm.~Exclusion Criteria:~Patients who fulfill any of the following criteria will be excluded:~* \> 65 years of age.~* Special type histology (mucinous, papillary, medullary, or tubular breast cancer), when pN0.~* ER, PgR and HER-2 status (via in situ hybridization or immunohistochemistry) not determined.~* Presence of distant metastases.~* Previous chemotherapy in the neoadjuvant setting.~* Non-ambulatory or WHO performance status \> 1.~* Pregnant or lactating women. Women of childbearing potential (menstruating within 6 months of study entry or with no hysterectomy and age \< 55) with either a positive or no pregnancy test at baseline.~* Women of childbearing potential unless using a reliable and appropriate contraceptive method. (Post-menopausal women must have been amenorrheic for at least 6 months to be considered of non-childbearing potential).~* More than 12 weeks between breast surgery and date of randomization.~* Organ allografts with immunosuppressive therapy required.~* Major surgery (except breast surgery) within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery.~* Participation in any investigational drug study within 4 weeks preceding treatment start.~* Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.~* History of another malignancy within the last five years except cured basal cell carcinoma of skin or carcinoma in situ of the uterine cervix.~* Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not well controlled with medication) or myocardial infarction within the last 12 months.~* Abnormal laboratory values:~  * Hemoglobin \< 10.0 g/dL, neutrophils \< 1.5 x 10\^9/L, platelet count \< 120 x 10\^9/L;~ * Serum creatinine \> 1.5 x Upper Limit of Normal (ULN);~ * Creatinine clearance (calculated per Cockroft and Gault) \< 50 mL/min;~ * Serum bilirubin \> ULN;~ * ALAT \> 1.5 x ULN;~ * Alkaline phosphatase \> 2.5 x ULN.~* Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.~* Lack of physical integrity of the upper gastrointestinal tract or those who have clinically significant malabsorption syndrome.~* Inability to swallow tablets.~* Life expectancy of less than 3 months.~* Unwilling or unable to comply with the protocol for the duration of the study.~* Requirement for concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).